Advancing Early Lung Cancer Detection Symposium

PUBLISHED ON May 15, 2019

bioAffinity Technologies proudly will present at Advancing Early Lung Cancer Detection at the Cleveland Clinic, an invitation-only symposium that brings together clinical experts, advocacy groups and industry leaders working to advance new technologies and methods necessary to find lung cancer at its earliest stages.

read more

bioAffinity Technologies Announces Formation of Scientific and Medical Advisory Board; M. Patricia Rivera, MD, Joins Board as Chair

PUBLISHED ON March 12, 2019

San Antonio, TX (March 12, 2019)  bioAffinity Technologies, a privately held biotech company, today announced the formation of a Scientific and Medical Advisory (SMA) Board to provide independent expert advice and counsel on the Company’s research and development of innovative cancer diagnostics and therapeutics, including CyPath® Lung.

read more

bioAffinity Technologies Selected as Finalist for Cancer Innovation Award

PUBLISHED ON March 6, 2019

San Antonio, TX (March 6, 2019) Healthcare innovators Lyfebulb and Helsinn selected bioAffinity Technologies, a privately held biotech company developing diagnostics and therapeutics for cancer, as one of 10 finalists for the second annual in Oncology. The Innovation Award recognizes groundbreaking work to advance the prevention and management of cancer.

read more

bioAffinity Technologies Announces Award of Canadian Patent

PUBLISHED ON February 5, 2019

SAN ANTONIO, TX (February 4, 2019) bioAffinity Technologies, a privately held biotech company, announced that the Canadian Intellectual Property Office has awarded a patent expanding the Company’s claims associated with its proprietary CyPath© technology for the early detection of cancer.

read more